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Abstract
Background: Aim of this prospective study was to compare clinical and genetic findings in children with idiopathic
or heritable pulmonary arterial hypertension (I/HPAH) with children affected with congenital heart defects
associated PAH (CHD-APAH).
Methods: Prospectively included were 40 consecutive children with invasively diagnosed I/HPAH or CHD-APAH
and 117 relatives. Assessment of family members, pedigree analysis and systematic screening for mutations in TGFß
genes were performed.
Results: Five mutations in the bone morphogenetic protein type II receptor (BMPR2) gene, 2 Activin A receptor
type II-like kinase-1 (ACVRL1) mutations and one Endoglin (ENG) mutation were found in the 29 I/HPAH children.
Two mutations in BMPR2 and one mutation in ACVRL1 and ENG, respectively, are described for the first time. In the
11 children with CHD-APAH one BMPR2 gene mutation and one Endoglin gene mutation were found. Clinical
assessment of relatives revealed familial aggregation of the disease in 6 children with PAH (HPAH) and one
CHD-APAH patient. Patients with mutations had a significantly lower PVR.
Conclusion: Mutations in different TGFß genes occurred in 8/29 (27.6%) I/HPAH patients and in 2/11 (18.2%)
CHD-APAH patients and may influence the clinical status of the disease. Therefore, genetic analysis in children with
PAH, especially in those with I/HPAH, may be of clinical relevance and shows the complexity of the genetic
background.
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Introduction
Pulmonary arterial hypertension (PAH) is a very rare
disease in childhood and can occur idiopathic (IPAH),
heritable (HPAH) or associated with various diseases
(APAH) including congenital heart defect (CHD-APAH)
[1]. As soon as familial aggregation or a genetic defect
has been identified in IPAH patients they will be classified
as HPAH. The true incidence of IPAH, HPAH or
CHD-APAH has not yet been established [2]. However,
estimates are around 2.2 new cases per million per year
in the general population [3] suggesting that a few
hundred children are affected in Germany. Children
with I/HPAH can have similar clinical presentation as
CHD-APAH patients with identical histological findings
including plexiform lesions [4].
I/HPAH and CHD-APAH are the most frequent cause
for PAH in children [5]. The classification of paediatric
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patients into these groups is difficult in some cases
because they often present with multiple symptoms and
clinical manifestations [6]. Furthermore, PAH in infancy is
frequently associated with genetic syndromes [6]. In 13%
of children with pulmonary hypertension chromosomal
anomalies such as Trisomy 21 are reported [7].
It is well known that genetic factors predispose some
individuals to develop PAH [2]. Especially heterozygous
mutations in the bone morphogenetic protein receptor
type II (BMPR2) gene on chromosome 2q33 were found
in > 70-80% of adult PAH patients with familial history
of disease [8-12]. In sporadic IPAH patients without
reported familial history of the disease and in children,
BMPR2 mutations were identified much less frequently
(in 10-40% of cases [9,13-15]). BMPR2 mutations are
even less common in patients with CHD-APAH.
Therefore, an additional genetic background has been
postulated [16].
Previous studies suggested that adult BMPR2 mutation
carriers are younger at diagnosis with a more severe
hemodynamic compromise [12,17]. Patients carrying an
activin A receptor type II-like 1 (ACVRL1) mutation
have been characterized to be even younger at diagnosis
and death, compared to patients with BMPR2 mutations
or without mutations [18]. Similar results have been
seen in a mixed cohort with 15 adult and 8 paediatric
mutation carriers [15]. There are no correlation studies
yet comparing genetic and clinical findings especially in
children with PAH. Two recent studies have identified
mutations in the ACVRL1 (also known as ALK1) gene
in several paediatric I/HPAH cases [14,19]. In a child
with PAH followed by the development of heritable
hemorrhagic telangiectasia (HHT) a mutation in the
Endoglin (ENG) gene has been found [20]. Very recently
two mutations in the SMAD9 gene were reported in
children diagnosed with HPAH [21,22]. Thus, PAH in
infancy seems to have a heterogeneous genetic background.
Until now, only a few studies investigated the prevalence of
mutations in the genes participating in the TGFß signalling
pathway in children systematically. They consisted of small
numbers of paediatric PAH patients and predominantly
the BMPR2 gene was analysed. The aim of this study was
to perform a broad and systematic screening for mutations
in BMPR2, ACVRL1, ENG, SMAD1, SMAD5 and SMAD9
genes and to compare clinical and genetic findings in a




Forty unrelated children under the age of 14 years
participated in this study. The diagnoses I/HPAH and
CHD-APAH were established at the participating PH
centers according to current guidelines [1,23]. In all
patients a detailed family history was obtained and a
pedigree was constructed. Relatives of index patients
underwent detailed clinical examination as described
previously [16,24]. All index patients underwent a detailed
clinical work up including right heart catheterization and
acquisition of age at onset and age at diagnosis. Their
parents gave written informed consent for this study,
which was approved by the Ethics Committee of the
University of Heidelberg.
Molecular genetic analysis
Genomic DNA was extracted from peripheral blood
leukocytes of patients and relatives. The entire coding
regions and the exon/intron boundaries of the BMPR2,
ACVRL1, ENG, SMAD1, SMAD5 and SMAD9 genes were
PCR amplified followed by denaturing high-performance li-
quid chromatography (DHPLC) as previously described [9]
and/or direct sequenced using BigDye Terminator Kit v1.1
and the ABI 3100 genetic analyzer (Applied Biosystems,
Foster City, CA). In mutation carriers all first degree
relatives, if available, were investigated for the mutation
identified in the index patient. Primers and amplification
procedures are available upon request. Pathogenicity of
identified sequence alterations was assessed by use of
the in silico prediction programs “PolyPhen” [25], and
“MutationTaster” [26], “SIFT” [27], and Alamut v2.2
(Interactive Biosoftware, [28]). For detection of whole
exonic deletions /duplications the Multiplex Ligation-
dependant Probe Amplification (MLPA) technique was
applied according to the manufacturer’s instructions
(MRC-Holland, Amsterdam).
Statistical analysis
Hemodynamic values are given as mean values ± standard
deviations and 95% confidence intervals. We compared
I/HPAH with CHD-APAH and mutation carriers vs.
non carriers, respectively, with respect to baseline
characteristics and hemodynamic parameters by two-
tailed students t-test and Chi-square tests using SPSS 20
(IBM SPSS Statistics V20 IBM Corporation). P values below
0.05 were considered statistically significant.
Results
Study population
Between January 2008 and May 2012 40 children with
PAH and 117 relatives of 20 index patients participated
in the study. Due to pedigree analysis and clinical work
up 29 children were classified as I/HPAH and 11 as
CHD-APAH patients (10 atrial septal defect = ASD II,
one ventricular septal defect = VSD, Figure 1). By pedigree
analysis and clinical assessment of relatives in 6 initially as
IPAH classified patients and in one patient with CHD-
APAH familial aggregation of the disease was observed with
at least one further affected family member (diagnosed by
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right heart catheterization) (Figure 2). One HPAH
(B7944, Figure 2) and two IPAH patients (K6735 and
K17353, pedigrees not shown), respectively belong to
consanguineous families. In 23 of the 29 IPAH and in
10/11 CHD-APAH patients pedigree analysis and
assessment of relatives (n = 69) revealed no familial
aggregation of the disease. One of the IPAH cases had a
suspected Russell-Silver syndrome, a clinically hetero-
geneous condition characterized by severe intrauterine
growth retardation, poor postnatal growth, craniofacial
features and a variety of minor malformations.
Identification of mutations
In 10 of the analyzed 40 children a mutation could be
identified: 8 in I/HPAH, 2 in CHD-APAH. Two mutations
were detected in patients with familial aggregation of the
disease (1 HPAH, 1 CHD-APAH), and 8 in clinically spor-
adic IPAH cases (Table 1, Figure 2). Seven of the identified
mutations have been previously described (4 in BMPR2, 1
in ACVRL1, and two in ENG). We identified three so far
not described sequence variants: two in the BMPR2 gene
(c.419-10 T >C and p.R890GfsX6) and one in the ACVRL1
gene (p.I317T, Table 1, Figure 2). Their functional relevance
was assessed using the computer prediction programs. The
frame shift mutation p.R890fsX6 was clearly classified as
mutation since it leads to premature insertion of a stop
codon. The amino acid Ile on position 317 of the ACVRL1
protein is highly conserved and therefore the identified
variant p.I317T is classified as mutation. The third novel
variant is a potential splice site mutation c.419-10 T >C.
We could not perform analysis of mRNA on the functional
level since the child already died. The in silico prediction
analysis did not reveal definitive results; therefore, this vari-
ant could be a mutation or a non-deleterious polymorph-
ism. For the summary statistics it has been counted as
BMPR2 mutation.
The two mutations identified in ENG (1 in CHD-APAH
and one in IPAH) were previously described in patients
with HHT [29,30]. Both, patients and their mutation
positive but unaffected family members in our cohort did
not show any sign of HHT. In five of I/HPAH and in two
CHD-APAH patients the identified mutations were also
identified in asymptomatic family members (in 6 parents, 3
grandparents, 1 aunt and 1 sister). No mutations were
identified in any of the analysed SMAD genes.
Table 1 lists all identified mutations, the type of
alteration, their location in the gene, gender, the age at
diagnosis, and clinical classification. New identified
mutations of the investigated genes are indicated by
asterisks. Common and rare polymorphisms without
disease relevance have also been detected in all investigated
genes (data not shown).
Distribution and frequency of mutations
The 5 BMPR2 mutations identified in the study popula-
tion were: 2 point mutations (1 nonsense mutation and 1
missense mutation), 1 frameshift mutation (small deletion)
and 2 large deletions, and 1 potential splice site mutation
(at the splice acceptor site), The nonsense, frameshift
mutation and deletion of exons 4 to 5 resulted in a pre-
mature termination of the protein. Both ACVRL1 and
ENG mutations were missense mutations. The BMPR2
mutations were distributed throughout the gene
whereas the ACVRL1 mutations were found only in the
11 CHD-APAH 29 I/HPAH
40 children with PAH 




2 with mutation 9 without 
mutation 
7 female/4 male 
6.9±4.7 years 
6 fam. HPAH/23 IPAH 
18 female/11 male 
5.2±4.3 years
8 with mutation
Figure 1 Genetic disposition of the study population. The figure shows the proportion of mutation carriers and non carriers in the study
population, female to male proportion and the mean age at diagnosis. I/HPAH = idiopathic/hereditary pulmonary arterial hypertension, CHD-
APAH = congenital heart disease associated pulmonary arterial hypertension. One BMPR2 variant has been classified as mutation but could
represent a mutation or a non-deleterious polymorphism.
Pfarr et al. Respiratory Research 2013, 14:3 Page 3 of 9
http://respiratory-research.com/content/14/1/3
serine/threonine protein kinase domain and the two
ENG mutations were located in the endoglin/CD105
domain. The distribution of the mutations across the
genes is shown in Figure 3.
Clinical and hemodynamic characteristics
The mean age at diagnosis of all 40 investigated children
was 6.0 ± 3.6 years. 25 children were females and 15
males reflecting a female to male ratio of 1.7:1 (Figure 1).
Children carrying a mutation (Table 1, Figure 2) had a
significantly lower pulmonary vascular resistance (PVR)
than patients without mutation (Table 2). Further clinical
parameters at diagnosis listed in Table 2 did not signifi-
cantly differ between mutation carriers and non carriers.
HPAH patients carrying a BMPR2 mutation were older
than those carrying an ACVRL1 or the patient with the
ENG mutation. Gender distribution ratios (female : male)
were congruent in I/HPAH and CHD-APAH (1.9:1 vs.
1.8:1, p = 0.613) and also mean age at diagnosis (5.2 ±
4.3 years vs. 6.9 ± 4.7 years, p = 0.352). Both groups did not
significantly differ in any of the analysed hemodynamic
parameters (Table 2). Mean age at onset of first symptoms
did not significantly differ between groups.
Discussion
The results of the study indicate that the proportion of
genetic alterations in children with various forms of
PAH is higher than previously thought and is related to
several different genes of the TGFß pathway. Mutations
of the BMPR2, ACVRL1, and ENG gene, respectively,
occurred in 8 out of 29 (27.5%) of I/HPAH patients and




























































Figure 2 Pedigrees of HPAH/CHD-APAH patients with identified mutations. The figure represents pedigree trees of children with mutations.
The index patient of each family is marked by an arrow. All family members with manifest PAH are shown in black. Family members in whom the
diagnosis HPAH is questionable are shown in grey. Healthy family members have open symbols and those who were heterozygous for the
identified mutation are referred to as “carrier”. Not tested family members are indicated by question mark. Pedigrees 1 to 8 represent families of
I/HPAH patients and pedigrees 8 and 9 families of CHD-APAH patients. The numbering of the pedigrees corresponds to the appearance of the
patients in Table 1. Mutations in the BMPR2 gene in I/HPAH patients were found in families 1 to 4. The BMPR2 sequence variant in family 5
which we classified as mutation could represent a mutation or a non-deleterious polymorphism. ACVRL1 mutations were present in families 6
and 7, and the ENG mutation in family 8. In CHD-APAH patients mutations were identified in BMPR2 (family 9) and ENG (family 10).
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carrying a mutation had a significantly lower PVR than non
carriers. Two BMPR2 and one ACVRL1 mutation detected
in this study have not been described before. Genetic
analysis in children with various forms of PAH may be
of clinical relevance and shows the complexity of the
genetic background in childhood.
Prevalence of gene alterations in children with I/HPAH
The prevalence of the here identified mutations in 27.5% of
I/HPAH patients in the BMPR2, ACVRL1 and ENG genes
is similar as previously reported. In 22% of 18 I/HPAH-chil-
dren Harrison et al. found mutations in these 3 genes [14].
Rosenzweig et al. found in 10% of patients BMPR2 muta-
tions [15]. In contrast to these 3 genes sequence alterations
of the SMAD genes (SMAD1, SMAD5 and SMAD9) seem
to be a rare event in adult or paediatric PAH patients (<2%)
with unclear functional significance [22]. In this study we
identified no mutation in any of the SMAD genes, but 3
rare polymorphisms in SMAD9 in 3 I/HPAH patients.
Genetic findings in children with CHD-APAH and
classification
The findings of this study (mutations in 18.2%) confirm
that gene defects play also a role in CHD-APAH-patients.
However, BMPR2 mutations have been a rare finding in
CHD-APAH and occurred in only 6% of cases of a mixed
cohort of adults and children [31]. In our CHD-APAH-
patient we found a deletion of the first exon of the BMPR2
gene which has been previously observed only in I/HPAH
[32,33]. Although such deletions are predicted to cause an
altered translation, their penetrance is variable and clinically
unaffected mutation carriers have also been reported [33]
and have been seen in the sister of our index patient.
HPAH and CHD-APAH are simultaneously present in this
family. Thus, the classification in HPAH and CHD-APAH
according to the guidelines [1,34] seems to be difficult in
this case since both forms can occur in one patient.
Mutations of ACVRL1/ENG and HHT in childhood
This study shows that ACVRL1 and ENG mutations can
cause the development of severe PAH in childhood,
without any symptoms or familial history of HHT. Wide
intrafamilial phenotypic variations were previously
observed in carriers of a mutation at position 484 [35].
Some of the mutation carriers in these families showed
symptoms of HHT, others of pulmonary hypertension
and one a combination of both phenotypes [35], as was
seen in our family with altered amino acid at this
Table 1 Clinical and genetic characteristics of mutation carriers
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10 C3783 m 13 CHD-APAH (ASDII);
Congenital hip
dislocation
no ENG missense Exon
12
c.1633 G > A
(p.G545S)
6 - 1
*marked mutations are described for the first time in this study; ? = unknown, n. a. = not available; FM family member; ASD atrial septal defect; VSD Ventricular
septal defect; HHT hereditary hemorrhagic telangiectasia; † deceased, # unclassified: mutation or non-deleterious polymorphism.
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position (p.R484Q). The novel mutation p.I317T identified
in patient A3385 was also present in three unaffected family
members. Neither the index patient nor the mutation
carriers in this family showed any clinical signs of HHT
and occurrence of HHT was also not reported in the
family history.
In our cohort we have detected two missense mutations
in the ENG gene: one in a patient with IPAH (A15836, p.
G214S), and one in a patient with CHD-APAH (D3783).
ENG mutations are quite common in HHT patients and
both mutations have previously been described in patients
with HHT only [29-31]. In our patients neither the index
patient nor any of the mutation positive family members
showed any clinical signs of HHT.
The ENG mutations identified in a CHD-APAH patient
and in an IPAH patient without phenotypic appearance of
HHT sheds new light on the variability of the phenotype
caused by defects in TGFß pathway genes. Both mutations
lead to an exchange from a highly conserved glycine residue
to a serine residue but are located on different sites of the
protein: p.G214S at the N-terminal and p.G545S at the C-
terminal part of the endoglin/CD105 domain. They are both
considered to be damaging predicted by PolyPhen [25].
Beside the here identified genetic defects in children
with I/HPAH and CHD-APAH there are most likely
further not yet identified genetic factors, in some families
possibly inherited in a recessive mode of inheritance as
previously suggested [16].
Clinical relevance of genetic alterations
We compared hemodynamic parameters between the 10
mutation carriers and 30 non carriers. In our study,
patients with mutation had a significantly lower PVR
than patients without mutation. Due to the small number
of patients we cannot exclude that this difference could
have been accidentally occurred particularly with respect
to the not significantly different PVRI. Rosenzweig et al.
[15] found no significant differences in PVRI between
mutation carriers and non carriers as well. These com-
parisons are anyhow difficult with respect to the genetic
heterogeneity in this population.
I/HPAH vs. CHD-APAH
In this study we did not find significant differences in
hemodynamic parameters or age at onset between I/HPAH
and CHD-APAH patients. This is in contrast to data from
Barst et al. [36] and Hill et al. [37] who both found a
significantly higher PVRI and an older age at onset of the
disease in I/HPAH patients. Again this might be due to the
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exon 1 exons 4-5
BMPR2 genomic level
ACVRL1 Transcript








Serine/Threonine protein kinase domainuntranslated region
GS domain
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ENG Transcript p.G545S
cytoplasmatic domain deletion
Endoglin/CD105 (Zona pellucida-like domain)
mutation
p.G214S
mutation or non-deleterious polymorphism
Figure 3 Location of the identified mutations in the genes BMPR2, ACVRL1, and ENG. The figure shows the location of all identified
mutations in the investigated genes. Larger deletions are shown as line above the genomic gene region, point mutations (nonsense and
missense), splice site mutations, frameshift mutations and small deletions are marked as arrows. The green arrow denotes the BMPR2 sequence
variant which was classified as mutation but could represent a mutation or non-deleterious polymorphism. Boxes represent exons, and the
colours of the boxes represent the different domains.
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Table 2 Clinical characteristics at diagnosis
Baseline parameters I/HPAH CHD-APAH Mutation carriers Non carriers
n 29 11 10 30
Female/male ratio 18/11 7/4 5/5 20/10
Baseline and hemodynamic parameters
p-value Mean ± SD 95% CI for
the mean
Mean ± SD 95% CI for
the mean
p-value Mean ± STD 95% CI for
the mean
Mean ± STD 95% CI for
the mean
Age of onset at first
symptoms (years)
0.974 4.4 ± 3.9 3.0-5.9 4.5 ± 3.9 2.1-6.8 0.419 5.3 ± 4.1 2.8-7.8 4.1 ± 3.8 2.8-5.5
Age at diagnosis by
RHC (years)
0.352 5,2 ± 4.3 3.1-7.3 6.9 ± 4.7 4.0-9.8 0.503 7.1 ± 4.1 3.5-10.7 5.6 ± 4.5 4.7-7.5
Heart rate per minute 0.744 98 ± 35 79-118 94 ± 15 84-105 0.776 93.4 ± 21.3 74.7-112.1 97.8 ± 31.3 82.4-113.1
Oxygen Saturation (%) 0.140 95.0 ± 6.5 91.6-98.4 81.8 ± 31.8 61.0-102.5 0.448 97.3 ± 2.2 95.1-99.4 88.3 ± 22.7 78.1-98.5
PASP (mm Hg) 0.799 87.3 ± 49.4 61.4-113.2 82.1 ± 23.8 65.5-99.7 0.275 64.5 ± 5.7 58.9-70.1 90.5 ± 45.4 69.0-112.1
PADP (mm Hg) 0.939 38.9 ± 26.1 24.7-53.1 39.8 ± 16.1 26.9-52.8 0.169 25.0 ± 11.1 14.1-35.9 43.0 ± 24.0 30.9-55.2
PAMP (mm Hg) 0.864 58.0 ± 33.0 40.0-76.0 55.5 ± 16.3 42.4-68.6 0.298 43.6 ± 6.6 37.3-50.2 60.8 ± 31.0 45.1-76.5
PCWP (mm Hg) 0.691 6.9 ± 3.3 5.1-8.8 6.2 ± 3.5 3.1-9.3 0.691 6.0 ± 4.4 1.1-10.9 6.9 ± 3.1 5.2-8.5
SASP (mm Hg) 0.998 93.7 ± 14.1 86.3-101.1 93.7 ± 13.0 85.7-101.8 0.871 94.6 ± 8.7 87.0-102.2 93.5 ± 14.5 87.0-100.0
SADP (mm Hg) 0.853 52.1 ± 16.2 43.6-60.6 53.1 ± 6.8 48.7-57.3 0.295 58.0 ± 5.4 53.2-62.8 51.1 ± 14.0 44.8-57.4
Cardiac Index (L/min/m2) 0.563 3.3 ± 1.1 2.6-3.9 3.7 ± 0.8 2.8-4.5 0.644 3.6 ± 1.1 2.6-4.7 3.3 ± 1.0 2.7-3.9
PVRI (Wood U*m2) 0.461 18.6 ± 16.1 9.8-27.4 12.9 ± 6.2 7.5-18.3 0.179 8.5 ± 2.5 6.1-10.9 19.4 ± 15.2 11.5-27.4
PVR (dyn*s*cm−5) 0.804 2012.2 ± 1788.8 1039.8-2984.5 1795.4 ± 1038.8 884.9-2705.9 0.014* 927.0 ± 284.4 1039.8-2984.5 2244.8 ± 1692.5 884.9-2705.9
Values are mean ± Standard Deviation = SD; RHC right heart catheterization, CI confidence interval, PASP pulmonary arterial systolic pressure, PAMP mean pulmonary arterial pressure, PADP diastolic pulmonary arterial
pressure; PCWP pulmonary capillary wedge pressure; SASP Systemic systolic arterial pressure; SADP systemic diastolic arterial pressure, PVRI pulmonary vascular resistance index.












larger cohorts are needed to investigate the differences
between I/HPAH and CHD-APAH.
In conclusion, mutations in different TGFß genes
occurred in 8 out of 29 I/HPAH patients and 2 out of 11
CHD-APAH-patients and may influence the clinical
status of the disease. Therefore, genetic analysis in children
with PAH may be of clinical relevance and shows the
complexity of the genetic background.
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